The rising cost of specialty drugs to treat complex, chronic or life-threatening conditions has the potential to break the pocket books of businesses, consumers, insurance companies and the state, according to Milam Ford of Blue Cross and Blue Shield of Louisiana. Read More
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More
April 28, 2015 Note: Distributing the New York Times article below is not an… Read More
This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.” Read More
Reaction from National Coalition on Health Care President and CEO John Rother… Read More
Will the cost of new hepatitis C treatments bust state budgets? A new analysis… Read More
The debate over the price of specialty drugs is intensifying and could well be… Read More